

2. (twice amended) A compound comprising a peptide of about 10 to 100 amino acids which mimics the binding specificity of an antibody, which peptide is identified by a method comprising:

1 p23

- (a) screening a first random peptide library with an antibody or antigen-binding derivative thereof that specifically binds to an antigen of interest, to identify a first peptide that specifically binds to said antibody or antigen-binding derivative thereof; and
- (b) screening a second random peptide library of peptides of about 10 to 100 amino acids which is the same or different from said first random peptide library with a compound comprising said first peptide identified in step (a) or a specific binding portion thereof, to identify a second peptide which binds to said compound and which mimics the binding specificity of said antibody.

C1
3. (amended) The compound of claim 2, in which said first random peptide library is a different library from said second random peptide library.

4. (amended) The compound of claim 2, in which said first random peptide library is the same library as said second random peptide library.

6. (twice amended) A compound comprising a peptide of about 10 to 100 amino acids which mimics the binding specificity of an antibody, which peptide is identified by a method comprising:

C2

- (a) screening a first random peptide library with an antibody or antigen-binding derivative thereof, to identify a plurality of different first peptides each of which specifically binds to said antibody or antigen-binding derivative thereof;
- (b) comparing the sequences of said plurality of different first peptides identified as binding said antibody or antigen-binding

derivative thereof in step (a), to identify a consensus binding sequence; and

C2
CONT

(c) screening a second random peptide library of peptides of about 10 to 100 amino acids which is the same or different from said first random peptide library with a compound comprising said consensus binding sequence, to identify a second peptide which binds to said compound and which mimics the binding specificity of said antibody.

C3

8. (twice amended) The compound of claim 2 in which the antibody

is the monoclonal antibody 7E11-C5 which is a murine IgG1 monoclonal antibody which binds specifically to human prostate carcinoma cell line LNCaP, as produced by the hybridoma deposited with the ATCC and assigned accession number HB 10494.

C4

10. (twice amended) The compound of claim 2 in which the library of step (a) or step (b) is a library of recombinant vectors that express a plurality of heterofunctional fusion proteins comprising random peptides, said fusion proteins comprising a binding domain encoded by an oligonucleotide comprising unpredictable nucleotides in which the unpredictable nucleotides are arranged in one or more contiguous sequences, wherein the total number of unpredictable nucleotides is greater than or equal to about 15 and less than or equal to about 600, and an effector domain that enhances expression or detection of the binding domain.

C5

27. (twice amended) A composition comprising the compound of claim 2; and a carrier.

C6

30. (twice amended) A composition comprising the compound of claim 8; and a pharmaceutically acceptable carrier.

C7

36. (twice amended) A compound comprising a peptide of about 10 to 100 amino acids which mimics the binding specificity of an antibody, which peptide is